Cargando…
Activating mutations and senescence secretome: new insights into HER2 activation, drug sensitivity and metastatic progression
HER2 amplification and overexpression is observed in approximately 20% of breast cancers and is strongly associated with poor prognosis and therapeutic responsiveness to HER2 targeted agents. A recent study by Bose and colleagues suggests that another subset of breast cancer patients without HER2 am...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3672670/ https://www.ncbi.nlm.nih.gov/pubmed/23634980 http://dx.doi.org/10.1186/bcr3406 |